Merck Sharp & Dohme Corp. has disclosed pyrazolopyrimidine derivatives acting as DNA polymerase inhibitors reported to be useful for the treatment of herpes virus infection.

Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. and Hangzhou Hertz Pharmaceutical Co. Ltd. have described apoptosis regulator Bcl-2 wild-type, Bcl-2 (D103Y mutant) and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.

Oncobix Co. Ltd. has divulged novel heterocyclic-substituted pyrimidine derivatives acting as ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Shanghai Visonpharma Co. Ltd. has identified pyridine[4,3-d]pyrimidine compounds acting as Toll-Like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer and viral infection.

The U.S. Department of Health and Human Services has synthesized cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, metabolic, psychiatric, neurological, pain, gastrointestinal, inflammation, and substance abuse and dependence.

Nanjing Zenshine Pharmaceuticals Co. Ltd. has disclosed fused heterocyclic compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.

Yingxi Intelligent Technology (Shanghai) Co. Ltd. has identified substituted monocyclic or bicyclic heterocyclic compounds acting as fibroblast growth factor receptor (FGFR) inhibitors and reported to be useful for the treatment of asthma, cancer, chronic heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammation, autoimmune and Parkinson’s disease, among others.

Cannabidiol derivatives potentially useful for the treatment of Parkinson’s disease and epilepsy have been described in a Deyi Pharmaceutical Co. Ltd. patent.

Suzhou Puhe Biopharma Co. Ltd. researchers have prepared and tested substituted bicyclic heteroaryl compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Research at Vrise Therapeutics Inc. has led to the development of 5,6,7,8-tetrahydro-2,6-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) inhibitors and thus reported to be useful for the treatment of cancer.